藥明生物(02269.HK)合營藥明海德訂立疫苗生產合同 合約價值最高達30億美元
格隆匯2月18日丨藥明生物(02269.HK)公告,內容有關Wu Xi Biologics Investments Limited與一家全球疫苗巨頭訂立意向書。
於2020年2月14日,公司與上海海利生物技術股份有限公司(一家於上海證券交易所上市的公司(股份代號:603718))共同設立的合營企業Wu Xi VaccinesIreland Limited(藥明海德)與疫苗合作伙伴就疫苗產品訂立總合約生產合同,據此,藥明海德須於愛爾蘭建設集原液及製劑生產以及質量控制實驗室於一體的綜合疫苗生產基地,併為疫苗合作伙伴生產及供應若干疫苗產品,初步期限由2020年2月14日起至2039年12月31日,且疫苗合作伙伴可額外續新三年,總合約價值最高達約30億美元。預期基地將於2022年開始營運。
訂立疫苗生產合同開創了疫苗行業全新合作模式、表明集團享譽全球疫苗CDMO(合同開發與生產外包)業務市場並展示本集團領先的技術優勢和全球高標準質量體系。
董事會認為,疫苗生產合同項下擬進行交易乃於本公司日常業務過程中進行,而疫苗生產合同的條款乃根據正常商業條款訂立,屬公平合理並符合本公司與其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.